AcquisitionsApr 27, 2026, 04:33 PM
SNSE acquired Faeth; $200M PIPE; proposes name change to FTH
AI Summary
Sensei Biotherapeutics (SNSE) acquired Faeth Therapeutics on February 17, 2026, issuing Series B Preferred Stock convertible into 10.5M common shares. Concurrently, SNSE completed a $200 million private placement, issuing 14.4M Series B Preferred shares. Stockholders will vote on converting these shares, increasing authorized common stock to 300M, and approving new equity plans. If approved, the company plans to rebrand as Faeth Therapeutics, Inc. and trade under the symbol FTH.
Key Highlights
- Acquired Faeth Therapeutics on February 17, 2026.
- Issued 10,497.0980 Series B Preferred shares to Faeth stockholders.
- Completed $200M private placement, issuing 14,440.395 Series B Preferred shares.
- Proposes to increase authorized common stock from 12.5M to 300M shares.
- Post-acquisition ownership: Faeth equityholders 40.6%, PIPE investors 54.5%.
- Proposes company name change to "Faeth Therapeutics, Inc." and ticker to "FTH".
- Annual Meeting on June 10, 2026, to vote on 7 proposals.